Y-mAbs Therapeutics Stock (NASDAQ: YMAB) stock price, news, charts, stock research, profile.
Open | $14.920 |
Close | $14.710 |
Volume / Avg. | 189.796K / 399.765K |
Day Range | 14.355 - 15.128 |
52 Wk Range | 4.600 - 20.900 |
Market Cap | $643.961M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 46 |
Short Interest | 6.13% |
Days to Cover | 6.73 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Y-mAbs Therapeutics (NASDAQ: YMAB) through any online brokerage.
Other companies in Y-mAbs Therapeutics’s space includes: ARS Pharmaceuticals (NASDAQ:SPRY), Cabaletta Bio (NASDAQ:CABA), 89bio (NASDAQ:ETNB), Zentalis Pharma (NASDAQ:ZNTL) and Cogent Biosciences (NASDAQ:COGT).
The latest price target for Y-mAbs Therapeutics (NASDAQ: YMAB) was reported by HC Wainwright & Co. on Wednesday, March 6, 2024. The analyst firm set a price target for 22.00 expecting YMAB to rise to within 12 months (a possible 49.56% upside). 14 analyst firms have reported ratings in the last year.
The stock price for Y-mAbs Therapeutics (NASDAQ: YMAB) is $14.71 last updated April 26, 2024 at 4:43 PM EDT.
There are no upcoming dividends for Y-mAbs Therapeutics.
Y-mAbs Therapeutics’s Q1 earnings are confirmed for Tuesday, May 7, 2024.
There is no upcoming split for Y-mAbs Therapeutics.
Y-mAbs Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.